MiMedx Group Inc (MDXG.OQ)
18 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|77||2009||Chairman of the Board, Chief Executive Officer|
|48||2011||President, Chief Operating Officer, Director|
|58||2010||Chief Financial Officer|
|42||2015||General Counsel, Secretary|
- BRIEF-MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of Amniofix® Injectable For Treatment Of Osteoarthritis Of The Knee
- BRIEF-Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable
- BRIEF-MiMedx Says "Confident" in Q1 Rev Guidance, Discloses DoJ Investigation
- BRIEF-Mimedx's Amniofix Injectable Granted RMAT Designation By FDA
- BRIEF-MiMedx Receives Notice Of Filing Delinquency From Nasdaq